The Search for Enhanced Therapeutic Index in Breast Cancer: Targeting the Tumor and Modulation of Enzyme Expression

REFERENCES

• Ryberg M., Nielsen D., Osterlind K., Skovsgaard T., Dombernowsky P. Prognostic Factors and Long-Term Survival in 585 Patients with Metastatic Breast Cancer Treated with Epirubicin-Based Chemotherapy. Ann. Oncol. 2001; 12: 81–87
   PubMed Web of Science ®Google Scholar
• Rahman Z., Frye D., Smith T., Asmar L., Theriault R., Budzar A.G.N. Results and Long Term Follow-up of 1581 Patients with Metastatic Breast Cancer Treated with Standard Dose Dodorubicin-Containing Chemotherapy: A Reference. Cancer 1999; 85: 104–111
   PubMed Web of Science ®Google Scholar
• Stockler M., Wilcken N., Ghersi D., Simes R. Systemic Reviews of Chemotherapy and Endocrine Therapy in Metastatic Breast Cancer. Cancer Treat. Rev. 2000; 26: 151–168
   PubMed Web of Science ®Google Scholar
• Budman D., Calabro A., Kreis W. In Vitro Evaluation of Synergism or Antagonism with Combinations of New Cytotoxic Agents. Anti-cancer Drugs 1998; 9: 687–702
   Google Scholar
• Budman D., Calabro A., Wang L., Liu X., Stiel L., Adams L., Kreis W. Synergism of Cytotoxic Effects of Vinorelbine and Paclitaxel In Vitro. Cancer Investig. 2000; 18: 695–701
   PubMed Web of Science ®Google Scholar
• Courtneidge S., Plowman G. The Discovery and Validation of New Drug Targets in Cancer. Curr. Opin. Biotechnol. 1998; 9: 632–636
   PubMed Web of Science ®Google Scholar
• Oetzel C., Jonuleit T., Gotz A., van der Kuip H., Michels H., Duster J., Hallek M., Aulitzky W. The Tyrosine Kinase Inhibitor CGP 5718 (STI 571) Induces Apoptosis in BCR-ABL Positive Cells by Downregulating BCL-X. Clin. Cancer Res. 2000; 6: 1958–1968
   PubMed Web of Science ®Google Scholar
• Pegram M., Konecny G., Slamon D. The Molecular and Cellular Biology of HER2/Neu Gene Amplification/Overexpression and the Clinical Development of Herceptin (Trastuzumab) Therapy for Breast Cancer. Cancer Treat. Res. 2000; 103: 57–75
   PubMedGoogle Scholar
• Moghaddam A., Zhang H.T., Fan T.P., Hu D.E., Lees V.C., Turley H., Fox S.B., Gatter K.C., Harris A.L., Bicknell R. Thymidine Phosphorylase Is Angiogenic and Promotes Tumor Growth. Proc. Natl Acad. Sci. USA 1995; 92: 998–1002
   PubMed Web of Science ®Google Scholar
• Fox S.B., Westwood M., Moghaddam A., Comley M., Turley H., Whitehouse R.M., Bicknell R., Gatter K.C., Harris A.L. The Angiogenic Factor Platelet-Derived Endothelial Cell Growth Factor/Thymidine Phosphorylase Is Up-Regulated in Breast Cancer Epithelium and Endothelium. Br. J. Cancer 1996; 73: 275–280
   PubMed Web of Science ®Google Scholar
• Toi M., Hoshina S., Taniguchi T., Yamamoto Y., Ishitsuka H., Tominaga T. Expression of Platelet-Derived Endothelial Cell Growth Factor/Thymidine Phosphorylase in Human Breast Cancer. Int. J. Cancer 1995; 64: 79–82
   PubMed Web of Science ®Google Scholar
• Matsumura M., Chiba Y., Lu C., Amaya H., Shimomatsuya T., Horiuchi T., Muraoka R., Tanigawa N. Platelet-Derived Endothelial Cell Growth Factor/Thymidine Phosphorylase Expression Correlated with Tumor Angiogenesis and Macrophage Infiltration in Colorectal Cancer. Cancer Lett. 1998; 128: 55–63
   PubMed Web of Science ®Google Scholar
• Hata K., Kamikawa T., Arao S., Tashiro H., Katabuchi H., Okamura H., Fujiwaki R., Miyazaki K., Fukumoto M. Expression of the Thymidine Phosphorylase Gene in Epithelial Ovarian Cancer. Br. J. Cancer 1998; 79: 1848–1854
   Web of Science ®Google Scholar
• Suzuki K., Morita T., Hashimoto S., Tokue A. Thymidine Phosphorylase/Platelet-Derived Endothelial Cell Growth Factor (PF-ECGF) Associated with Prognosis in Renal Cell Carcinoma. Urol. Res. 2001; 29: 7–12
   PubMed Web of Science ®Google Scholar
• Brown N.S., Bicknell R. Thymidine Phosphorylase, 2-Deoxy-d-Ribose and Angiogenesis. Biochem. J. 1998; 334: 1–8
   PubMed Web of Science ®Google Scholar
• Ishitsuka H., Miwa M., Takemoto K., Fukuoka K., Itoga A., Maruyama H. Role of Uridine Phosphorylase for Antitumor Activitiy of 5′-Deoxy-5 Fluorouridine. Gann 1980; 71: 112–123
   PubMedGoogle Scholar
• Ishitsuka H. Capecitabine: Preclinical Pharmacology Studies. Investig. New Drugs 2000; 18: 343–354
   PubMed Web of Science ®Google Scholar
• Koizumi W., Saigenji K., Nakamaru N., Okayasu I., Kurihara M. Prediction of Response to 5′-Deoxy-5-Fluorouridine (5′-DFUR) in Patients with Inoperable Advanced Gastric Cancer by Immunostaining of Thymidine Phosphorylase/Platelet-Derived Endothelial Cell Growth Factor. Oncology 1999; 56: 215–222
   PubMed Web of Science ®Google Scholar
• Budman D., Lichtman S. Investigational Drugs. The Chemotherapy Sourcebook. 2, M. Perry. Williams & Wilkins, Baltimore 1996; 479–558
   Google Scholar
• Meropol N.J. Oral Fluoropyrimidines in the Treatment of Colorectal Cancer. Eur. J. Cancer 1998; 34: 1509–1513
   PubMed Web of Science ®Google Scholar
• Ishikawa T., Sawada N., Sekiguchi F., Fukase Y., Ishitsuka H. Xeloda (Capecitabine), a New Oral Fluoropyrimidine Carbamate with an Improved Efficacy Profile over Other Fluoropyrimidines (Meeting Abstract). Proc. Annu. Meet. Am. Soc. Clin. Oncol. 1997; 16: 796a
   Google Scholar
• Cao S., Lu K., Ishitsuka H., Rustum Y.M. Antitumor Efficacy of Capecitabine Against Fluorouracil-Sensitive and -Resistant Tumors (Meeting Abstract). Proc. Annu. Meet. Am. Soc. Clin. Oncol. 1997; 16: 795a
   Google Scholar
• Schuller J., Cassidy J., Dumont E., Roos B., Durston S., Banken L., Utoh M., Mori K., Weidekamm E., Reigner B. Preferential Activation of Capecitabine in Tumor Following Oral Administration to Colorectal Patients. Cancer Chemother. Pharmacol. 2000; 45: 291–297
   PubMed Web of Science ®Google Scholar
• Findlay M., Van Cutsem E., Kocha W., Allman D., Laffranchi B., Griffin T., Osterwalder B., Dalley D., Pazdur R., Verweij J. A Randomized Phase II Study of Xeloda (Capecitabine) in Patients with Advanced Colorectal Cancer (Meeting Abstract). Proc. Annu. Meet. Am. Soc. Clin. Oncol. 1997; 16: 798a
   Google Scholar
• Bunnell C.A., Winer E.P. Oral 5-FU Analogues in the Treatment of Breast Cancer. Oncology 1998; 12: 39–43
   PubMed Web of Science ®Google Scholar
• Pazdur R., Hoff P.M., Medgyesy D., Royce M., Brito R. The Oral Fluorouracil Prodrugs. Oncology 1998; 12: 48–51
   PubMed Web of Science ®Google Scholar
• Blum J.L., Jones S.E., Buzdar A.U., LoRusso P.M., Kuter I., Vogel C., Osterwalder B., Burger H.U., Brown C.S., Griffin T. Multicenter Phase II Study of Capecitabine in Paclitaxel-Refractory Metastatic Breast Cancer. J. Clin. Oncol. 1999; 17: 485–493
   PubMed Web of Science ®Google Scholar
• Blum J. The Role of Capecitabine, an Oral, Enzymatically Activated Fluoropyrimidine, in the Treatment of Metastatic Breast Cancer. Oncologist 2001; 6: 56–64
   PubMed Web of Science ®Google Scholar
• Patterson A.V., Zhang H., Moghaddam A., Bicknell R., Talbot D.C., Stratford I.J., Harris A.L. Increased Sensitivity to the Prodrug 5′-Deoxy-5-Fluorouridine and Modulation of 5-Fluoro-2′-Deoxyuridine Sensitivity in MCF-7 Cells Transfected with Thymidine Phosphorylase. Br. J. Cancer 1995; 72: 669–675
   PubMed Web of Science ®Google Scholar
• Ishikawa T., Sekiguchi F., Fukase Y., Sawada N., Ishitsuka H. Positive Correlation Between the Efficacy of Capecitabine and Doxifluridine and the Ratio of Thymidine Phosphorylase to Dihydropyrimidine Dehydrogenase Activities in Tumors in Human Cancer Xenografts. Cancer Res. 1998; 58: 685–690
   PubMed Web of Science ®Google Scholar
• Kurosumi M., Tabei T., Suemasu K., Inoue K., Kusawake T., Sugamata N., Higashi Y. Enhancement of Immunohistochemical Reactivity for Thymidine Phosphorylase in Breast Carcinoma Cells After Administration of Docetaxel as a Neoadjuvant Chemotherapy in Advanced Breast Cancer Patients. Oncol. Rep. 2000; 7: 945–948
   PubMed Web of Science ®Google Scholar
• Sawada N., Ishitsuka H., Sekiguchi F., Tanaka Y., Ishitsuka H. X-Ray Irradiation Induces Thymidine Phosphorylase and Enhances the Efficacy of Capecitabine (Xeloda) in Human Cancer Xenografts. Clin. Cancer Res. 1999; 5: 2948–2953
   PubMed Web of Science ®Google Scholar
• Endo M., Shinbori N., Fukase Y., Sawada N., Ishitsuka H., Tanaka Y. Induction of Thymidine Phosphorylase Expression and Enhancement of Efficacy of Capecitabine or 5′-Deoxy-5- Fluorouridine by Cyclophosphamide in Mammary Tumor Models. Int. J. Cancer 1999; 83: 127–134
   PubMed Web of Science ®Google Scholar
• Sawada N., Ishikawa T., Fukase Y., Nishida M., Yoshikubo T., Ishitsuka H. Induction of Thymidine Phosphorylase Activity and Enhancement of Capecitabine Efficacy by Taxol/Taxotere in Human Cancer Xenografts. Clin. Cancer Res. 1998; 4: 1013–1019
   PubMed Web of Science ®Google Scholar
• Fujimoto-Ouchi K., Tanaka Y., Tominaga T. Schedule Dependency of Antitumor Activity in Combination Therapy with Capecitabine/5′-Deoxy-5-Fluorouridine and Docetaxel in Breast Cancer Models. Clin. Cancer Res. 2001; 7: 1079–1086
   PubMed Web of Science ®Google Scholar
• Figgitt D., Wiseman L. Docetaxel: An Update of Its Use in Advanced Breast Cancer. Drugs 2000; 59: 621–651
   PubMed Web of Science ®Google Scholar
• Pronk L., Vasey P., Sparreboom A., Reigner B., Planting A., Gordon R., Osterwalder B., Verweij J., Twelves C. A Phase I and Pharmacokinetic Study of the Combination of Capecitabine and Docetaxel in Patients with Advanced Solid Tumours. Br. J. Cancer 2000; 83: 22–29
   PubMed Web of Science ®Google Scholar
• O'Shaughnessy J., Vukelja S., Moiseyenko V., Miles D., Cervantes G., Chan Navarro C., Mauriac L., Van Hazel G., Lui W.-Y., Ayoub J.-P., Rizel S., Osterwalder B., Rutman O., Leonard R. Results of a Large, Phase III Trial of Xeloda/Taxotere Combination Therapy Versus Taxotere Monotherapy in Patients with Metastatic Breast Cancer. Annu. San Antonio Breast Cancer Symp. 2000; 23: 381a
   Google Scholar
• Budman D., Calabro A. In Vitro Search for Synergy and Antagonism: Evaluation of Docetaxel Combinations in Breast Cancer Cell Lines. Breast Cancer Res. Treat. 2002; 74: 41–46
   PubMed Web of Science ®Google Scholar
• Rosso R., Del Mastro L., Durando A., Garrone O., Cherubini R., Scotto T., Genta F., Occelli M., Bellino R., Bighin C., Catzeddu T., Stevani I., Baldini A., Lambiase A., Venturini M. Capecitabine in Association with Epirubicin and Docetaxel as a First Line Treatment in Advanced Breast Cancer. A Multicenter Phase II Study. Breast Cancer Res. Treat. 2001; 69: 353a
   Google Scholar
• Rosen L. Irinotecan in Lymphoma, Leukemia, and Breast, Pancreatic, Ovarian, and Small-Cell Lung Cancers. Oncology 1998; 12(Suppl. 6)103–109
   PubMedGoogle Scholar
• Hardman W., Moyer M., Cameron I. Efficacy of Treatment of Colon, Lung, and Breast Human Carcinoma Xenografts with: Doxorubicin, Cisplatin, Irinotecan or Topotecan. Anticancer Res. 1999; 19: 2269–2274
   PubMed Web of Science ®Google Scholar
• Ikeda H., Koshiba R. A Pilot Study of Irinotecan Hydrochloride for Metastatic Breast Cancer—Efficacy as a Salvage Therapy. Gann 2000; 27: 723–727
   Google Scholar
• Brangi M., Litman T., Ciotti M., Nishiyama K., Kohlhagen G., Takimoto C., Robey R., Pommier Y., Fojo T., Bates S. Camptothecin Resistance: Role of the ATP-Binding Cassette (ABC), Mitoxanthrone-Resistance Half-Transporter (MXR), and Potential for Glucuronidation in MXR-Expressing Cells. Cancer Res. 1999; 59: 5938–5946
   PubMed Web of Science ®Google Scholar
• Kawabata S., Oka M., Shiozawa K., Tsukamoto K., Nakatomi K., Soda H., Fukuda M., Ikegami Y., Sugahara K., Yamada Y., Kamihira S., Doyle L., Ross D., Kohno S. Breast Cancer Resistance Protein Directly Confirms SN-38 Resistance of Lung Cancer Cells. Biochem. Biophys. Res. Commun. 2001; 280: 1216–1223
   PubMed Web of Science ®Google Scholar
• Cunningham D., Maroun J., Vanhoefer U., Van Cutsem E. Optimizing the Use of Irinotecan in Colorectal Cancer. Oncologist 2001; 6: 17–23
   PubMed Web of Science ®Google Scholar
• Cao S., Rustum Y. Synergistic Antitumor Activity of Irinotecan in Combination with 5-Fluorouracil in Rats Bearing Advanced Colorectal Cancer: Role of Drug Sequence and Dose. Cancer Res. 2000; 60: 3717–3721
   PubMed Web of Science ®Google Scholar
• Falcone A., Di Paolo A., Masi G., Allegrini G., Danesi R., Lencioni M., Pfanner E., Comis S., Del Tacca M., Conte P. Sequence Effect of Irinotecan and Fluorouracil Treatment on Pharmacokinetics and Toxicity in Chemotherapy-Naive Metastatic Colorectal Cancer Patients. J. Clin. Oncol. 2001; 19: 3456–3462
   PubMed Web of Science ®Google Scholar
• Cao S., Hapke G., Rustum Y. Enhanced Antitumor Activity of Xeloda by Irinotecan in Nude Mice Bearing Human A253 and FaDu Head and Neck Xenografts. Proc. Am. Assoc. Cancer Res. 2001; 42: 464a
   Google Scholar
• Budman D. Capecitabine. Investig. New Drugs 2000; 18: 355–363
   PubMed Web of Science ®Google Scholar
• Rothenberg M., Meropol N., Poplin E., Van Cutsem E., Wadler S. Mortality Associated with Irinotecan Plus Bolus Fluorouracil/Leucovorin: Summary Findings of an Independent Panel. J. Clin. Oncol. 2001; 19: 3801–3807
   PubMed Web of Science ®Google Scholar